Literature DB >> 10037478

Analysis of a novel mechanism of neuronal toxicity produced by an apolipoprotein E-derived peptide.

K L Moulder1, M Narita, L K Chang, G Bu, E M Johnson.   

Abstract

The apolipoprotein E (apoE)-derived peptide (141-155)2 has a neurotoxic effect, implying that apoE itself could be a source of toxicity in Alzheimer's disease brain. We characterized the toxicity of this peptide on superior cervical ganglion (SCG) neurons and compared the death with the apoptotic death that occurs after nerve growth factor (NGF) deprivation in these cells. A dose of 10 microM apoE (141-155)2 resulted in the death of approximately 50% of the neurons within 24 h. Nuclear condensation and DNA fragmentation preceded the death. However, most inhibitors of NGF deprivation-induced death, including the caspase inhibitor Boc-aspartyl(O-methyl)fluoromethyl ketone and genetic deletion of bax-/-, had no effect on the toxicity. Inclusion of depolarizing levels of potassium did block the toxicity. Receptor-associated peptide (RAP), an antagonist for apoE receptors, did not protect cells in either SCG or hippocampal cultures. In addition, RAP had no effect on internalization of the apoE peptide. These data support the observation that apoE (141-155)2 is neurotoxic but suggest that the neurotoxicity is distinct from classical apoptosis or necrosis. Furthermore, these results indicate that the toxic effect may occur independently of members of the low-density lipoprotein receptor gene family.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10037478     DOI: 10.1046/j.1471-4159.1999.0721069.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  6 in total

1.  Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity.

Authors:  M Tolar; J N Keller; S Chan; M P Mattson; M A Marques; K A Crutcher
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

2.  Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases.

Authors:  Y Hashimoto; H Jiang; T Niikura; Y Ito; A Hagiwara; K Umezawa; Y Abe; Y Murayama; I Nishimoto
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

3.  Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord.

Authors:  I Tesseur; J Van Dorpe; K Bruynseels; F Bronfman; R Sciot; A Van Lommel; F Van Leuven
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

4.  Full-length apolipoprotein E protects against the neurotoxicity of an apoE-related peptide.

Authors:  K A Crutcher; H N Lilley; S R Anthony; W Zhou; V Narayanaswami
Journal:  Brain Res       Date:  2009-10-21       Impact factor: 3.252

5.  ApoE mimetic peptide decreases Abeta production in vitro and in vivo.

Authors:  S Sakura Minami; Antoinette Cordova; John R Cirrito; Joseph A Tesoriero; Lenard W Babus; Gary C Davis; Sivanesan Dakshanamurthy; R Scott Turner; Daniel Ts Pak; G William Rebeck; Mikell Paige; Hyang-Sook Hoe
Journal:  Mol Neurodegener       Date:  2010-04-20       Impact factor: 14.195

6.  A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity.

Authors:  Ling Guo; Mary Jo LaDu; Linda J Van Eldik
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.